|
|
Adverum Biotechnologies Inc (NASDAQ: ADVM) |
|
*Market share is calculated based on total revenue.
News about Adverum Biotechnologies Inc Contracts |
April 25, 2025
Adverum Biotechnologies, Inc. Under Investor Scrutiny Amidst Comparatively Stagnant Performance Pomerantz Law Firm, a highly respected and longstanding authority in securities litigation, has recently announced an investigation on behalf of investors in Adverum Biotechnologies, Inc. This investigation serves to delve into potential claims concerning the company, particularly centered on investor grievances. Interested parties are encouraged to reach out to Danielle Peyton at Pomerantz for further guidance and clarification.This scrutiny comes at a tumultuous time for Adverum Biotechnologies, marked by financial stagnation and contrasting performance metrics when placed alongside industry competitors. Analyzi...
|
November 18, 2024
Advancements in Gene Therapy for Wet AMD: Adverum Biotechnologies Sets a New Standard with Ixo-vec In an era where innovative therapies are paramount in managing ocular diseases, Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage biotech firm based in Redwood City, California, is at the forefront of redefining treatment options for wet age-related macular degeneration (AMD). The company recently announced compelling data from its LUNA and OPTIC clinical trials, showcasing the long-term efficacy and safety of its gene therapy candidate, Ixo-vec.The 52-week data from the LUNA trial, coupled with a substantial follow-up from the OPTIC trial extending to four years, bolster the argument for Ixo-vec ...
|
July 17, 2024
Positive Interim Results from Adverum Biotechnologies? LUNA Phase 2 Trial Presented at 2024 ASRS Annual Meeting Adverum Biotechnologies recently announced encouraging interim findings from its LUNA Phase 2 clinical trial for Ixo-vec (initially known as ADVM-022), at the 2024 Annual Meeting of the American Society of Retina Specialists (ASRS). Ixo-vec, a gene therapy product candidate intended for the treatment of wet age-related macular degeneration (wet AMD), has demonstrated significant promise in its 26-week analysis. Key Highlights of the 26-Week Interim Analysis Efficacy Data : The interim results highlight Ixo-vec s potential as a leading product candidate. Key efficacy metrics indicate substantial p...
|
Publicly Traded Peers of Adverum Biotechnologies Inc
Xeris Biopharma Holdings Inc
Share Performance
+150.26%
One Year
|
Xeris Biopharma Holdings Inc
Profile
Xeris Biopharma Holdings Inc's business model focuses on developing and commercializing innovative therapeutics for various medical conditions.
More about Xeris Biopharma Holdings Inc 's Market Share
|
Ocugen Inc
Share Performance
+30.52%
This Quarter
|
Ocugen Inc
Profile
Ocugen Inc's business model is focused on the development and commercialization of innovative gene therapies to treat rare and underserved ocular diseases, with a particular emphasis on underserved patient populations. They aim to leverage their expertise in gene therapy and partnerships to advance novel treatments and bring them to market, ultimately improving the lives of patients in need.
More about Ocugen Inc 's Market Share
|
Hoth Therapeutics Inc
Share Performance
-27.62%
One Year
|
Hoth Therapeutics Inc
Profile
Hoth Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for dermatological disorders and other related conditions.
More about Hoth Therapeutics Inc's Market Share
|
Novabay Pharmaceuticals Inc
Share Performance
-11.89%
This Quarter
|
Novabay Pharmaceuticals Inc
Profile
Novabay Pharmaceuticals Inc. operates as a biopharmaceutical company that develops and commercializes non-antibiotic and anti-infective products to address unmet therapeutic needs in the healthcare industry. They focus on utilizing their proprietary technology platforms to provide innovative solutions for various eye, ear, and skin infections.
More about Novabay Pharmaceuticals Inc 's Market Share
|
Aura Biosciences Inc
Share Performance
-19.07%
One Year
|
Aura Biosciences Inc
Profile
Aura Biosciences Inc is a biotechnology company that focuses on developing and commercializing therapies to treat cancer. They utilize their proprietary Tumor Paint technology to selectively deliver light-activated drugs directly to tumors, aiming to improve treatment outcomes and minimize side effects.
More about Aura Biosciences Inc 's Market Share
|
Protara Therapeutics Inc
Share Performance
-24.52%
30 Days
|
Protara Therapeutics Inc
Profile
Protara Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies to address significant unmet medical needs. Their business model revolves around identifying and advancing potential drug candidates that target specific diseases or conditions, conducting extensive research and development to ensure safety and efficacy, and ultimately seeking regulatory approvals and entering the market to make these therapies accessible to patients worldwide. Protara leverages collaborations and partnerships within the healthcare industry to support their research efforts and drive business growth.
More about Protara Therapeutics Inc's Market Share
|
Bluebird Bio Inc
Share Performance
-74.26%
One Year
|
Bluebird Bio Inc
Profile
Bluebird Bio Inc's business model focuses on developing gene therapies for severe genetic diseases and cancer. They collaborate with academic and industry partners to leverage their gene editing and cell-based technologies for discovering potential treatments and advancing these therapies through clinical trials.
More about Bluebird Bio Inc 's Market Share
|
Regenxbio Inc
Share Performance
+25.45%
This Year
|
Regenxbio Inc
Profile
Regenxbio Inc is a biotechnology company that focuses on the development and commercialization of gene therapy treatments for various diseases. Their business model revolves around leveraging their proprietary gene delivery platform, NAV Technology, to license their technology and collaborate with other pharmaceutical companies to advance gene therapy programs. They generate revenue through licensing agreements, milestone payments, and royalties from their partners, while retaining the rights to develop their own internal pipeline of therapies.
More about Regenxbio Inc 's Market Share
|
Denali Therapeutics Inc
Share Performance
-8.14%
30 Days
|
Denali Therapeutics Inc
Profile
Denali Therapeutics Inc is a biotechnology company focused on developing and delivering effective therapies for neurodegenerative diseases. Their business model revolves around leveraging their deep knowledge of neurology and genetics to discover and develop innovative drugs. They aim to commercialize these therapies through strategic partnerships with pharmaceutical companies or through independent clinical development.
More about Denali Therapeutics Inc 's Market Share
|
Sarepta Therapeutics Inc
Share Performance
+6.48%
Over The Past 5 Days
|
Sarepta Therapeutics Inc
Profile
Sarepta Therapeutics Inc's business model centers around the research, development, and commercialization of innovative genetic medicines for rare diseases, with a particular focus on Duchenne muscular dystrophy (DMD).
More about Sarepta Therapeutics Inc 's Market Share
|
Liquidia Corporation
Share Performance
-17.58%
Over The Past 5 Days
|
Liquidia Corporation
Profile
Liquidia Corporation is a biopharmaceutical company that develops and commercializes products using its proprietary PRINT? technology to design and produce precision-engineered medicines. The company focuses on creating therapies for respiratory diseases and other areas of high unmet medical need, leveraging the potential of its unique particle engineering platform.
More about Liquidia Corporation's Market Share
|
Mirum Pharmaceuticals Inc
Share Performance
+11.18%
30 Days
|
Mirum Pharmaceuticals Inc
Profile
Mirum Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing innovative therapies for patients with rare liver diseases.
More about Mirum Pharmaceuticals Inc 's Market Share
|
Biogen Inc
Share Performance
-7.86%
This Quarter
|
Biogen Inc
Profile
Biogen Incs business model focuses on researching, developing, and commercializing innovative therapies primarily for neurological and neurodegenerative diseases, emphasizing advancements in precision medicine and patient care.
More about Biogen Inc 's Market Share
|
Amgen Inc
Share Performance
-8.74%
This Quarter
|
Amgen Inc
Profile
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
More about Amgen Inc 's Market Share
|
Alector Inc
Share Performance
+7.38%
Over The Past 5 Days
|
Alector Inc
Profile
Alector Inc's business model focuses on developing novel therapeutics for neurodegenerative diseases using its proprietary platform and partnering with pharmaceutical companies for clinical trials and commercialization.
More about Alector Inc 's Market Share
|
Coherus Biosciences inc
Share Performance
+1.85%
Over The Past 5 Days
|
Coherus Biosciences inc
Profile
Coherus Biosciences Inc is a biopharmaceutical company focused on developing and commercializing high-quality biosimilar therapeutics. Their business model revolves around leveraging their expertise in cell culture, protein purification, formulation development, and analytical methods to manufacture and market biosimilar products. By providing cost-effective alternatives to expensive biologic drugs, Coherus Biosciences aims to make healthcare more accessible and affordable for patients.
More about Coherus Biosciences inc 's Market Share
|
Halozyme Therapeutics Inc
Share Performance
+11.96%
This Year
|
Halozyme Therapeutics Inc
Profile
Halozyme Therapeutics Inc is a biotechnology company that primarily focuses on developing and commercializing novel oncology therapies. Their business model involves leveraging their proprietary enzyme technology to improve the delivery and effectiveness of therapeutic drugs. By partnering with pharmaceutical companies, Halozyme aims to license their technology and collaborate on the development and commercialization of innovative therapies for various diseases.
More about Halozyme Therapeutics Inc 's Market Share
|
Exelixis Inc
Share Performance
+26.28%
This Year
|
Exelixis Inc
Profile
Exelixis Inc's business model is focused on the discovery, development, and commercialization of innovative therapies for the treatment of cancer.
More about Exelixis Inc 's Market Share
|
Atara Biotherapeutics Inc
Share Performance
+3.04%
30 Days
|
Atara Biotherapeutics Inc
Profile
Atara Biotherapeutics Inc is a biotechnology company that focuses on developing therapies for patients with serious medical conditions. They utilize a personalized medicine approach to create off-the-shelf, allogeneic T-cell immunotherapies. By leveraging their expertise in T-cell immunotherapy and genetic engineering, they aim to provide innovative treatments with the potential for broad patient reach.
More about Atara Biotherapeutics Inc 's Market Share
|
Genenta Science S p a
Share Performance
+6.71%
Over The Past 5 Days
|
Genenta Science S p a
Profile
Genenta Science S.p.A. operates on a business model focused on the development of immuno-gene therapies for the treatment of cancer. They aim to leverage their proprietary technology to genetically modify autologous hematopoietic stem cells and engineer them to express immunomodulatory protein IL-12. These modified cells are then reinfused into patients to stimulate an immune response against tumors, potentially offering a novel and personalized approach to cancer treatment.
More about Genenta Science S p a 's Market Share
|
Meiragtx Holdings Plc
Share Performance
-22.03%
30 Days
|
Meiragtx Holdings Plc
Profile
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
More about Meiragtx Holdings Plc's Market Share
|
Lexeo Therapeutics Inc
Share Performance
-80.10%
One Year
|
Lexeo Therapeutics Inc
Profile
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
More about Lexeo Therapeutics Inc 's Market Share
|
Sources: Adverum Biotechnologies Inc and all companies mentioned above in this report
|
